NUVATION BIO INC CLASS A (NUVB)
Health Care · biotechnology · NYSE
Nuvation Bio is a clinical-stage oncology firm advancing a portfolio of targeted small-molecule therapies for patients with solid tumors, highlighted by its ROS1-positive NSCLC treatment, IBTROZI.
What NUVATION BIO INC CLASS A does
Nuvation Bio is a global oncology company focused on developing novel small-molecule therapies to address challenging cancers. The company's lead product is IBTROZI (taletrectinib), a ROS1 inhibitor approved for the treatment of ROS1-positive non-small cell lung cancer (NSCLC). Its pipeline also includes safusidenib, a brain-penetrant mIDH1 inhibitor currently in clinical development for IDH1-mutant glioma.
Themes: oncology drug development, ROS1+ NSCLC, IDH1-mutant glioma, small molecule inhibitors, targeted cancer therapy
Fundamentals
- Price$6.93 as of 2026-08-21 close
- Market cap$2.4B as of 2026-08-21
- 1-year return+152.9% 2025-08-21 close $2.74 → 2026-08-21 close $6.93
- P/En/a negative earnings
- Net margin-88.2% as of 2026-08-24
- Gross margin+88.2% as of 2026-08-24
- ROE-49.7% as of 2026-08-24
- Debt / equity1.63 as of 2026-08-24
- Revenue growth (YoY)+1083.6% as of 2026-08-24
- Beta1.60 as of 2026-08-24
- Last reported earnings2026-08-06 SEC EDGAR Form 8-K (Item 2.02)
How NUVB compares in its sector
- net profit marginmiddle range 504 covered Health Care peers, as of 2026-08-24
- operating marginmiddle range 504 covered Health Care peers, as of 2026-08-24
- gross margintop 25% 384 covered Health Care peers, as of 2026-08-24
- return on equitymiddle range 576 covered Health Care peers, as of 2026-08-24
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Top 10 scores & list membership
NUVB is not currently in any published Top 10 list. Its scores are below.
Long-term score
Not scored for the long-term list: no shareholder return data.
Short-term score
58.8 #282 of 1,704 scored · #61 of 240 in Health Care
Setup 72nd: no Elliott-wave labelling currently fits its swings; trend 70th: it is trading 14.0% above its 50-day average, the short-term trend line; weakest is catalysts 25th: analysts have cut their average price target by 5.1% since the prior reading.
Scores as of 21 Aug 2026. Each bar is a percentile: how this company ranked against every company the score ranked, 0–100. A list is a published formula and its output, not a recommendation. Method version 2.
How NUVATION BIO INC CLASS A looks technically
NUVATION BIO INC CLASS A (NUVB) is trading 18.1% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 9 trading days ago — a "golden cross", a bullish long-term signal. There is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 18, below the 25 that marks a real trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 59, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bullish about 3 trading days ago (its momentum flipped positive). It made a new 20-day high about 3 trading days ago. It is 28.9% below its highest point of the past year.
Trend
8
| Distance from the 200-day | it is trading 18.1% above its 200-day average, the long-term trend line — a longer-term uptrend | +18.1% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $6.08 | $6.08 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $5.87 | $5.87 |
| Swing structure | each recent peak has been higher than the one before it and each dip has been shallower — the pattern chart-watchers call an uptrend, which describes where price has already been and not where it goes next | higher highs and higher lows |
| Last swing turn | its last significant turn was a swing low 7 calendar days ago — the swings before that are what the structure reading is measured on | 7 sessions |
| Wave structure | its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five; the labelling fails if price closes below 5.88. It is one of several labellings that fit, and it describes the swings already printed, not what comes next. The same swings also read as a three-part correction in leg C. | possible upward five-wave sequence, in wave 3 (one of several readings) |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 9 trading days ago — a "golden cross", a bullish long-term signal | 9 sessions |
| Trend strength (14-day ADX) | there is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 18, below the 25 that marks a real trend) | 17.5 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 59, neither overbought (above 70) nor oversold (below 30) | 58.8 |
|---|---|---|
| Position in its 14-day range | it is trading in the upper half of its 14-day range ($5.88 to $7.58) — its "stochastic" reading is 62 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 61.8 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bullish about 3 trading days ago (its momentum flipped positive) | 3 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $9.75 | $9.75 |
|---|---|---|
| From the 52-week high | it is 28.9% below its 52-week high (its highest price of the past year) | -28.9% |
| Above the 52-week low | it is 169.6% above its 52-week low (its lowest price of the past year) | +169.7% |
| Below the 52-week high | it is 28.9% below its highest point of the past year | 28.9% |
| Since a 20-day breakout | it made a new 20-day high about 3 trading days ago | 3 sessions |
| Since a 55-day breakout | it made a new 55-day high about 3 trading days ago | 3 sessions |
| All-time high | its highest closing price on record is $15.23 (set on 2021-05-26) | $15.23 |
| Given back of the 52-week move | over the past year its closes ranged ($2.69 to $9.54), and it has given back roughly a third of its rise from last year’s low — 38% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $5.09 to $5.31. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 38.1% |
| From the all-time high | it is 54.5% below its all-time high | -54.5% |
| Nearest price level | it is trading 9.8% above a support level at $6.25 — a price it turned at twice since 2026-02-05, most recently on 2026-07-09. Since 2024-08-21 it has 15 such levels below the current price and 0 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -9.8% |
| All-time low | its lowest closing price on record is $0.95 (set on 2023-10-31) | $0.95 |
| Above the all-time low | it is 629.5% above its all-time low | +629.5% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are narrower than usual versus its own recent 6-month history (tighter than about 72% of it) | 28th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.4028 between its high and its low — about 5.8% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.4028 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $5.95 and $7.13 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $5.95 – $6.54 – $7.13 |
| Typical daily range (% of price) | its price moves about 5.8% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 5.8% |
| Stretch from the 200-day average | it is trading 2.6 daily ranges above its 200-day average price (18.1% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 2.6 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.98× |
|---|
Analyst
2
| Change in the average price target | analysts have raised their average price target by 8.0% since the prior reading | +8.0% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating has softened toward "sell" since the prior reading | 0.01 toward sell |
Candlestick patterns
2
| Since a doji | 7 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 7 sessions ago |
|---|---|---|
| Since a bearish engulfing | 1 session ago it opened above the previous session's close and finished below that session's open — a "bearish engulfing" pair, where one down day more than undid the up day before it | 1 session ago |
Price gaps
3
| Gap at the open | it opened on 2026-08-21 2.2% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and had not traded back through that level by the close | +2.2% |
|---|---|---|
| Open gap | it gapped 2.2% above the previous close today and has not traded back through the level it left behind at 6.83 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | +2.2% |
| Gap filled | a 2.9% gap up opened on 2026-08-19 has been "filled" 1 session ago — price traded back through the level the gap left behind, and it took 1 session to close | 1 session ago |
Price streaks
1
| Closing streak | it closed higher in its latest session, after a session that did not close higher — a single up day rather than a run | 1 session up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 5.4 percentage points (the stock gained 7.8% while the market gained 2.3%) | +5.5% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 41.6 percentage points (the stock gained 44.7% while the market gained 3.1%) | +41.6% |
| vs market, 6 months | over the past 6 months this stock beat the market by 16.3 percentage points (the stock gained 27.4% while the market gained 11.1%) | +16.3% |
| vs market, 12 months | over the past 12 months this stock beat the market by 132.4 percentage points (the stock gained 152.9% while the market gained 20.5%) | +132.4% |
Signal agreement
2
| Bullish technical signals | 6 of the 9 technical signals we can compute for it are currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, a fresh 20-day high, MACD momentum is positive, outperforming the market over 6 months, trading above the Ichimoku cloud — these describe past price behaviour, not a forecast | 6 of 9 |
|---|---|---|
| Bearish technical signals | 0 of the 9 technical signals we can compute for it are currently in a bearish state — these describe past price behaviour, not a forecast | 0 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 22% above the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-16 and projected forward over today's price, the side traders read as an established uptrend, with the band below acting as the level that would have to give way. The band itself is moderate, spanning 5.3% of the share price. | +21.6% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 23% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $5.64 — a volume-weighted average of daily closes over 155 sessions, not a true tick-by-tick VWAP. | +22.8% |
|---|---|---|
| Vs the average paid since it last reported | the price is 5% above the average price paid since it last reported on 2026-08-06 (its 10-Q), so the typical buyer over that stretch is showing a gain. That average is $6.59 — a volume-weighted average of daily closes over 12 sessions, not a true tick-by-tick VWAP. | +5.1% |
Price levels it has turned at before
NUVB last closed at $6.93 on 2026-08-21. Since 2024-08-21 it has turned at 15 prices below its last close and 0 above; the 3 nearest below are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $6.25 | Support | 9.8% below the last close | turned there twice · 2026-02-05 to 2026-07-09 |
| $5.90 | Support | 14.9% below the last close | turned there twice · 2026-02-27 to 2026-08-14 |
| $5.32 | Support | 23.2% below the last close | turned there four times · 2026-02-23 to 2026-07-17 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five.
This labelling fails — stops being a possible reading at all — if it closes below $5.88.
This is one of several labellings that fit the same swings, so treat it as a reading rather than the reading. It was chosen from 2 labellings that survived the rules, counting shorter readings of the same bars.
On past moves of this shape the leg has usually ended somewhere between $7.33 and $8.23 — that is where it has tended to end if the count holds, not a forecast of where the price goes.
Alternate reading: The same swings also read as a three-part correction in leg C, which fails on a close below $5.88.
This labelling was already in place when we began recording count changes on 2026-08-13, so how long it has stood is not something we can say yet.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Recent golden cross (50-day crossed above 200-day) · Pulled back from the 12-month high · Broke out to a new 20-day high · MACD just crossed bullish (12/26/9) · trendless / choppy (low ADX) | Learn: moving average · golden cross · adx · rsi · macd · breakout · fifty two week high low
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.45 mean, 1=Strong Buy…5=Strong Sell) — 10 analysts
- Mean price target$13.10 range $7.00 – $21.00; median $12.50
Analyst estimates, as of 2026-08-23. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for NUVB
- Consensus EPS estimate-$0.09 next reporting period, as of 2026-08-23
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Heavy reliance on the commercial success of IBTROZI (taletrectinib) and the clinical success of pipeline assets like safusidenib.","Significant history of operating losses and continued requirement for capital to fund clinical trials and commercialization.","Risks associated with regulatory approvals, intellectual property protection, and managing complex global partnerships."]
What changed in the latest 10-Q
AI-assisted comparison of NUVB's 10-Q filed 2026-05-04 against the prior one filed 2025-11-03.
Management's Discussion & Analysis (MD&A)
The two filings could not be meaningfully compared for this section.
Risk Factors
- Added:
- In January 2026, we announced a partnership with Eisai Co., Ltd. ("Eisai") to commercialize taletrectinib in Europe and other territories outside the U.S., China and Japan.
- In March 2026, we announced that the European Medicines Agency had validated the Marketing Authorisation Application ("MAA") for taletrectinib for the treatment of advanced ROS1+ NSCLC.
- On February 10, 2026, the outstanding warrants to purchase Class A Common stock expired and were delisted pursuant to a Form 25 filed by The New York Stock Exchange.
- In February 2026, we announced a protocol amendment to SIGMA study for safusidenib in IDH1-mutant glioma, which converted the study from a Phase 2 to a Phase 3 study.
- In March 2026, the Company announced that new data will be presented at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2026 taking place April 17–22, 2026, in San Diego, California.
- In March 2026, the Company has been named to Fast Company's 2026 list of the Most Innovative Companies—ranked #9 in the Medicines, Therapeutics, and Pharmaceuticals category.
- In March 2026, the Company appointed Stephen Dang, Ph.D., as Chief Legal Officer. Dr. Dang brings over 18 years of experience in the biopharmaceutical industry across all stages of the drug product life cycle.
- In April 2026, the Company has amended its existing exclusive license agreement for safusidenib with Daiichi Sankyo to include Japan in the territory rights licensed to the Company, effectively securing exclusive global safusidenib development and commercialization rights for the Company.
- Removed:
- Taletrectinib was previously granted Breakthrough Therapy Designations by both the U.S. FDA and China's National Medical Products Administration ("NMPA") for the treatment of patients with locally advanced or metastatic ROS1+ NSCLC.
- Our clinical-stage pipeline includes differentiated, novel oncology product candidates that have been generated from our proprietary drug discovery and development programs or acquired through business development activities:
- Safusidenib is being evaluated in the G203 study, which is currently a randomized phase 2 study for the maintenance treatment of high grade IDH1-mutant glioma with safusidenib against placebo. Following alignment with FDA, a protocol amendment is in progress to finalize G203 as a global Phase 3 study by increasing the study size to support potential regulatory approvals.
- NUV-1511 is our first clinical-stage drug-drug conjugate ("DDC"), which fuses a targeting agent to a widely used chemotherapy agent. NUV-1511 is being evaluated in a Phase 1/2 study in patients with advanced solid tumors who previously received and progressed on or after treatment with Enhertu® and/or Trodelvy® per approved U.S. FDA labeling, human epidermal growth factor receptor 2-negative ("HER2-") metastatic breast cancer, metastatic castration-resistant prostate cancer ("mCRPC"), advanced pancreatic cancer, and platinum-resistant ovarian cancer ("PROC"). We expect to provide an update from the Phase 1/2 dose escalation study of NUV-1511 in the second half of 2025.
- NUV-868 is a BD2-selective, oral, small molecule bromodomain and extra-terminal ("BET") inhibitor that inhibits BRD4. As previously announced, we are evaluating next steps for the NUV-868 program, including further development in combination with approved products for indications in which BD2-selective BET inhibitors may improve outcomes for patients.
- In September 2025, additional data from our pivotal Phase 2 TRUST-I and TRUST-II studies of taletrectinib was presented at the 2025 World Conference on Lung Cancer.
- In September 2025, Japan's MHLW approved IBTROZI for the treatment of adult patients with ROS1+ unresectable, advanced and/or recurrent NSCLC.
- In September 2025, we announced enrollment of the first patient in the taletrectinib Phase 3 TRUST-IV study for the adjuvant treatment of patients with resected ROS1+ NSCLC.
- In October 2025, we announced enrollment of the first patient in the safusidenib G203 study for the maintenance treatment of high-grade IDH1-mutant glioma.
- Reworded:
- FDA abbreviation changed from full "U.S. Food and Drug Administration ("FDA")" in older filing to "FDA" in newer filing (2026-05-04).
- Japan's regulatory body reference changed from "Ministry of Health, Labour, and Welfare ("MHLW")" in older filing to "Japan's MHLW" in newer filing (2026-05-04).
- China's regulatory body reference changed from "National Medical Products Administration ("NMPA")" in older filing to "China's NMPA" in newer filing (2026-05-04).
- Japan's partner reference changed from "Nippon Kayaku Co., Ltd" in older filing to "our partner NK" in newer filing (2026-05-04).
- China's partner reference changed from "Innovent Biologics (Suzhou) Co. Ltd. ("Innovent")" in older filing to "our partner Innovent" in newer filing (2026-05-04).
- Breakthrough Therapy Designation text changed from "for the treatment of patients with locally advanced or metastatic ROS1+ NSCLC" in older filing to "for the treatment of both TKI-naïve and TKI-pretreated disease patients with locally advanced or metastatic ROS1+ NSCLC" in newer filing (2026-05-04).
- Safusidenib study name and description changed from "G203 study" with "randomized phase 2 study" in older filing to "SIGMA study" with "randomized Phase 3 study" in newer filing (2026-05-04).
- Revenue description changed from "including upfront license fees" in older filing to "including upfront license fees and milestone payments" in newer filing (2026-05-04).
- Accumulated deficit changed from "$1,078.8 million" as of September 30, 2025 in older filing to "$1,110.0 million" as of March 31, 2026 in newer filing (2026-05-04).
- Notes:
- The newer filing text appears truncated at the end of the Financial Overview section, potentially affecting completeness of comparison.
- The older filing text also appears truncated, ending mid-word at "thir" in the final paragraph.
- Two recent developments sections exist in the documents with different content organization and dating.
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
1 open-market purchase and 3 open-market sales by insiders in the last 90 days.
- Last 90 days1 buy ($118250) · 3 sells ($1M) — 1 buying, 3 selling insiders
- Last 180 days1 buy ($118250) · 5 sells ($2M) — 1 buying, 4 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-06-23. As of 2026-08-24.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about NUVB's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
5 institutional 13F filers reported holding NUVB as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 86,739,685
- Reported value $372,113,251
reported quarterly holdings change (2025-12-31 → 2026-03-31): 1 new, 4 increased, 0 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
NUVB had 53,423,972 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
NUVB had 15.2% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 8.7 days to cover at the same settlement.
- Reported short interest (shares) 53,423,972
- Short interest (% of shares outstanding) 15.2%
- Prior settlement (shares) 55,668,014
- Reported change -4.03%
- Days to cover (reported) 8.7
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Pfizer (PFE)
- Novartis (NVS)
- AstraZeneca (AZN)
- Blueprint Medicines (BPMC)
- Turning Point Therapeutics (Bristol Myers Squibb - BMY)
- Agios Pharmaceuticals (AGIO)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare NUVB vs…
NUVATION BIO INC CLASS A is found in…
NUVB ranks in…
Frequently asked questions
What does NUVATION BIO INC CLASS A (NUVB) do?
Nuvation Bio is a global oncology company focused on developing novel small-molecule therapies to address challenging cancers. The company's lead product is IBTROZI (taletrectinib), a ROS1 inhibitor approved for the treatment of ROS1-positive non-small cell lung cancer (NSCLC). Its pipeline also includes safusidenib, a brain-penetrant mIDH1 inhibitor currently in clinical development for IDH1-mutant glioma.
What sector is NUVATION BIO INC CLASS A (NUVB) in?
NUVATION BIO INC CLASS A (NUVB) is classified in the Health Care sector. Its industry is biotechnology. It trades on NYSE.
Who are NUVATION BIO INC CLASS A's (NUVB) competitors?
Notable peers of NUVATION BIO INC CLASS A (NUVB) include Pfizer, Novartis, AstraZeneca, Blueprint Medicines and Turning Point Therapeutics (Bristol Myers Squibb - BMY). This peer set is informational only — not financial advice.
Is NUVATION BIO INC CLASS A (NUVB) overbought or oversold right now?
NUVATION BIO INC CLASS A (NUVB) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 59, in the neutral middle (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on NUVB come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.